Table.
Supramolecular biomaterials for cancer immunotherapy.
| Immunotherapeutic strategy | Supramolecular biomaterial | Function | Morphology | Immune agents | Reference |
|---|---|---|---|---|---|
| Immunogenic cell death | β-CD/ferricinium | Responsive domain | Nanoparticle | DOX | [57] |
| β-CD/adamantane | Carrier | Nanoparticle | ICG/I-MT/resiquimod | [58] | |
| Drug-polymer | Inducer | Nanoparticle | DOX | [64] | |
| C16-cypate-RRKK-PEG8-COOH | Inducer | Nanoparticle | Cypate | [66] | |
| FFG | Assembly domain | Nanoclusters | TPA-S-RDN | [73] | |
| Immune checkpoint blockade | GDFDFDY | Assembly domain | Hydrogel | DPPA-1/indoximod | [86] |
| SOPC | Carrier | Nanoparticle | Selumetinib/supratinib | [92] | |
| PLGLAG | Assembly domain | Nanotubes/hydrogel | Camptothecin/anti–PD-1 | [95] | |
| HA-DEG/UPy | Carrier | Hydrogel | DPPA-1 | [96] | |
| FFVLK | Assembly domain | Nanofiber/hydrogel | Tetraphenylethylene | [97] | |
| β-CD/adamantane | Carrier | Nanorod | CRISPR/Cas9/Au | [102] | |
| DC maturation | NapGFFpY-OMe | Assembly domain | Hydrogel | OVA | [135] |
| DNA network | Carrier | Hydrogel | CpG | [136] | |
| β-CD/adamantane | Carrier | Nanoparticle | Pt(IV)/CpG | [43] | |
| Macrophage regulation | DSPE-PEG2000 | Carrier | Nanoparticle | BLZ-945/selumetinib | [170] |
| β-CD/lysine | Carrier | Nanoparticle | Resiquimod | [172] | |
| M2pep | Responsive domain | Nanorod | M2pep/Au | [176] | |
| T lymphocyte activation | PEG2000 | Carrier | Nanoparticle | OVA/Bec1 | [183] |
| PLGLAG | Assembly domain | Nanoparticle | DPPA-1/NLG919 | [186] | |
| Poly-l-lysine | Carrier | Nanoparticle | Au/VC/carnosic acid | [187] | |
| MDSC depletion | Tadalafil/ICG/Fe3+ | Inducer/carrier | Nanoparticle | Tadalafil/ICG/Fe3+ | [199] |